10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024 DOI Open Access
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru

et al.

Diabetes Care, Journal Year: 2023, Volume and Issue: 47(Supplement_1), P. S179 - S218

Published: Dec. 11, 2023

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating Standards annually, or more frequently as warranted. For a detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.

Language: Английский

Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association DOI Open Access
Suzanne V. Arnold, Deepak L. Bhatt, Gregory W. Barsness

et al.

Circulation, Journal Year: 2020, Volume and Issue: 141(19)

Published: April 13, 2020

Although cardiologists have long treated patients with coronary artery disease (CAD) and concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a comorbidity that affected the development progression of disease. Over past decade, number factors shifted forced cardiology community to reconsider role in CAD. First, addition being associated increased cardiovascular risk, potential affect treatment choices for In this document, we discuss selection testing CAD, medical management (both secondary prevention strategies stable angina), revascularization strategy. Second, although glycemic control recommended as part comprehensive risk factor there is mounting evidence mechanism by which glucose managed can substantial impact on outcomes. intensity choice medications) It becoming clear cardiologist needs both consider decisions potentially help guide glucose-lowering medications. Our statement provides summary effective, patient-centered CAD T2DM, emphasis emerging evidence. Given increasing prevalence accumulating need decisions, knowledge will become ever more important optimize our patients’

Language: Английский

Citations

231
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol DOI Creative Commons
Peter W.F. Wilson, Tamar S. Polonsky, Michael D. Miedema

et al.

Journal of the American College of Cardiology, Journal Year: 2018, Volume and Issue: 73(24), P. 3210 - 3227

Published: Nov. 10, 2018

Language: Английский

Citations

199
Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis DOI
Xiao-Hua Yu, Dawei Zhang, Xi‐Long Zheng

et al.

Progress in Lipid Research, Journal Year: 2018, Volume and Issue: 73, P. 65 - 91

Published: Dec. 4, 2018

Language: Английский

Citations

182
Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75) DOI Open Access
Yasuyoshi Ouchi, Junichi Sasaki, Hidenori Arai

et al.

Circulation, Journal Year: 2019, Volume and Issue: 140(12), P. 992 - 1003

Published: Aug. 22, 2019

Background: Evidence regarding the primary prevention of coronary artery disease events by low-density lipoprotein cholesterol (LDL-C) lowering therapy in older individuals, aged ≥75 years, is insufficient. This trial tested whether LDL-C–lowering with ezetimibe useful for cardiovascular patients. Methods: multicenter, prospective, randomized, open-label, blinded end-point evaluation conducted at 363 medical institutions Japan examined preventive efficacy patients elevated LDL-C without history disease. Patients, who all received dietary counseling, were randomly assigned (1:1) to receive (10 mg once daily) versus usual care randomization stratified site, age, sex, and baseline LDL-C. The outcome was a composite sudden cardiac death, myocardial infarction, revascularization, or stroke. Results: Overall, 3796 enrolled between May 2009 December 2014, 1898 each control. Median follow-up 4.1 years. After exclusion 182 203 control because lack appropriate informed consent other protocol violations, 1716 (90.4%) 1695 (89.3%) included analysis, respectively. Ezetimibe reduced incidence (hazard ratio [HR], 0.66; 95% CI, 0.50–0.86; P =0.002). Regarding secondary outcomes, incidences (HR, 0.60; 0.37–0.98; =0.039) revascularization 0.38; 0.18–0.79; =0.007) lower group than group; however, there no difference stroke, all-cause mortality, adverse groups. Conclusions: prevented events, suggesting importance individuals years Given open-label nature trial, its premature termination issues follow-up, magnitude benefit observed should be interpreted caution. Clinical Registration: URL: https://www.umin.ac.jp . Unique identifier: UMIN000001988.

Language: Английский

Citations

182
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024 DOI Open Access
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru

et al.

Diabetes Care, Journal Year: 2023, Volume and Issue: 47(Supplement_1), P. S179 - S218

Published: Dec. 11, 2023

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating Standards annually, or more frequently as warranted. For a detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.

Language: Английский

Citations

178